Nevro (NYSE:NVRO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO) in a report published on Tuesday. The brokerage issued a hold rating on the medical equipment provider’s stock.

Other analysts have also recently issued reports about the stock. Truist Financial lowered their price objective on shares of Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Canaccord Genuity Group boosted their price target on Nevro from $4.00 to $5.85 and gave the company a “hold” rating in a research report on Friday, February 7th. Jefferies Financial Group upgraded Nevro from an “underperform” rating to a “hold” rating and raised their price objective for the stock from $4.50 to $5.85 in a report on Monday, February 10th. JMP Securities reiterated a “market perform” rating on shares of Nevro in a report on Tuesday, November 12th. Finally, Robert W. Baird increased their target price on shares of Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.43.

Nevro Trading Up 0.3 %

Shares of NVRO stock opened at $5.73 on Tuesday. The firm’s 50-day simple moving average is $4.56 and its 200-day simple moving average is $4.97. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. Nevro has a 1-year low of $3.16 and a 1-year high of $17.44. The firm has a market cap of $214.53 million, a P/E ratio of -3.03 and a beta of 0.91.

Institutional Investors Weigh In On Nevro

Institutional investors have recently bought and sold shares of the stock. Amundi bought a new position in shares of Nevro in the fourth quarter valued at approximately $30,000. Oxford Asset Management LLP acquired a new stake in Nevro in the fourth quarter worth approximately $39,000. Virtu Financial LLC bought a new position in Nevro during the 3rd quarter valued at $63,000. Corton Capital Inc. acquired a new position in shares of Nevro during the 4th quarter valued at $43,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Nevro in the fourth quarter valued at $45,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.